OBJECTIVE: The influence of @entity409 on the pharmacokinetics of @entity1564 , a long-acting selective AT1 subtype angiotensin II receptor antagonist was studied. METHODS: Twelve healthy subjects and 12 @entity1 with mild to moderate @entity409 received a single oral dose of 12 mg of @entity22666 on day 1 and once-daily doses of 12 mg on days 3-7. The drug was taken before breakfast. Serial blood samples were collected for 48 h after the first and last administration on days 1 and 7. Serum was analyzed for unchanged @entity1564 by HPLC with UV detection. RESULTS: The pharmacokinetic parameters on days 1 and 7 revealed no statistically significant influence of @entity409 on the pharmacokinetics of @entity1564 . Following single dose administration on day 1, the mean Cmax was 95.2 ng.ml-1 in healthy subjects and 109 ng.ml-1 in the @entity1 . The AUC0-infinity was 909 ng.h.ml-1 in healthy volunteers and 1107 ng.h.ml-1 in @entity1 and the elimination half-life was 9.3 h in healthy volunteers and 12 h in the @entity1 . At steady state on day 7, mean Cmax values were similar in both groups (112 vs 116 ng.ml-1); the AUC tau was 880 ng.h.ml-1 in healthy subjects and 1080 ng.h.ml-1 in @entity1 while the elimination half-life was 10 h in healthy subjects and 12 h in the @entity1 with @entity409 . The ACU0-infinity on day 1 was almost identical to the AUC tau on day 7. A moderate drug accumulation of 20%, which does not require a dose adjustment, was observed following once-daily dosing in both groups. No serious or severe adverse events were reported. CONCLUSION: Mild to moderate @entity409 has no clinically relevant effect on @entity1564 pharmacokinetics, and no dose adjustment is required for such @entity1 .

Pharmacokinetics and safety of @entity1564 cilexetil in subjects with normal and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity22666 :: ('MESH:C077793', 'Chemical') :: ['candesartan cilexetil'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver disease', 'liver impairment'] @entity1564 :: ('MESH:C081643', 'Chemical') :: ['candesartan']
@entity409 :: (MESH:D008107,Disease) :: ['impaired liver function']
